NIH Director Blogs About Value of Model Organisms in Drug Discovery Research

(Left) Untreated yeast cells, (Right) Treated yeast cells. Credit: Daniel Tardiff, Whitehead Institute.
Treating yeast cells with the NAB compound reverses the toxic effects of elevated levels of alpha synuclein protein. Credit: Daniel Tardiff, Whitehead Institute. View larger image

These eye-catching images and the NIGMS-funded research that yielded them were recently featured by NIH Director Francis Collins on his blog. Scientists led by a team at the Whitehead Institute for Biomedical Research engineered yeast to produce too much of a protein, alpha synuclein. In Parkinson’s disease, elevated levels or mutated forms of this protein wreak havoc on the cell. Using the model system, the researchers tested tens of thousands of compounds to identify any that reversed the toxic effects. One did. The compound, abbreviated NAB, worked similarly in an animal model and in rat neurons grown in a lab dish. Collins described the approach as “an innovative strategy for drug hunting that will likely be extended to other conditions.”

Learn more:

Using Model Organisms to Study Health and Disease Fact Sheet
Living Laboratories Chapter from The New Genetics Booklet

Post a Comment

Required fields are marked *

You may post as "anonymous." Your e-mail address will not be published; we may use it to contact you about your comment.

*

Please note: Comment moderation is enabled and may delay your comment. There is no need to resubmit your comment.